Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2025-09-09EMA Authorised: Revlimid (lenalidomide) — Bristol-Myers Squibb Pharma EEIG
The European Medicines Agency authorised Revlimid (lenalidomide) for multiple indications including multiple myeloma, mantle cell lymphoma, …
-
EMA approval · 2025-08-28EMA Authorised: Sarclisa (Isatuximab) — Sanofi Winthrop Industrie
The European Medicines Agency has authorised Sarclisa (isatuximab) for the treatment of multiple myeloma, decision date 18 July 2025.
-
EMA approval · 2025-08-21EMA Authorised: Ninlaro (ixazomib citrate) — Takeda Pharma A/S
EMA authorised Ninlaro (ixazomib citrate) for the treatment of multiple myeloma. The product has orphan medicine designation and Takeda Phar…
-
FDA approval · 2025-08-19FDA Approved: TECVAYLI — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for TECVAYLI (teclistamab-cqyv) from Janssen Biotech, Inc., resulting in an updated label that expan…
-
FDA approval · 2025-08-19FDA Approved: TALVEY — Supplemental Application (Janssen Biotech, Inc.)
The FDA approved a supplemental application for TALVEY (talquetamab) from Janssen Biotech, Inc.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2025-08-05FDA Approved: POMALIDOMIDE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application from Aurobindo Pharma Limited for pomalidomide, permitting the marketing of a generic pomalidomide p…
-
FDA approval · 2025-08-05FDA Approved: POMALIDOMIDE — Supplemental Application (Teva Pharmaceuticals, Inc.)
FDA approves Teva's supplemental application for pomalidomide (ANDA 209956), yielding a generic pomalidomide product.
-
FDA approval · 2025-08-05FDA Approved: POMALIDOMIDE — Supplemental Application (Natco Pharma Limited)
FDA approved a supplemental application for pomalidomide from Natco Pharma Limited, granting approval for this generic product.
-
EMA approval · 2025-07-22EMA Authorised: Lynozyfic (linvoseltamab) — Regeneron Ireland Designated Activity Company (DAC)
EMA authorised Lynozyfic (linvoseltamab) for multiple myeloma with conditional approval; Regeneron Ireland DAC is the marketing authorisatio…
-
EMA approval · 2025-07-14EMA Authorised: Pomalidomide Krka (Pomalidomide) — Krka, d.d., Novo mesto
The EMA authorised Pomalidomide Krka for the treatment of multiple myeloma.
-
FDA approval · 2025-07-08FDA Approved: ELREXFIO — Supplemental Application (U.S. Pharmaceuticals)
The FDA approved a supplemental application for ELREXFIO (elranatamab-BCMM) filed by U.S. Pharmaceuticals.
-
EMA approval · 2025-06-18EMA Authorised: Phelinun (melphalan hydrochloride) — ADIENNE S.r.l. S.U.
The EMA authorised Phelinun (melphalan hydrochloride) for multiple cancers including multiple myeloma, Hodgkin lymphoma, non-Hodgkin lymphom…
-
FDA approval · 2025-06-16FDA Approved: PLERIXAFOR — Original Application (Camber Pharmaceuticals, Inc.)
FDA approved a generic version of plerixafor (Mozobil) for mobilizing hematopoietic stem cells in adults with non-Hodgkin lymphoma or multip…
-
CLINICAL_TRIALS approval · 2025-06-15Clinical Trial Update: Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients
Teclistamab's expanded access treatment protocol for relapsed or refractory multiple myeloma has been approved for marketing. The sponsor is…
-
FDA approval · 2025-05-22FDA Approved: KYPROLIS — Supplemental Application (Onyx Pharmaceuticals, Inc.)
The FDA approved a supplemental application for KYPROLIS (carfilzomib) submitted by Onyx Pharmaceuticals, expanding the label and/or indicat…
-
FDA approval · 2025-05-22FDA Approved: LENALIDOMIDE — Original Application (Devatis Inc.)
FDA approved a generic lenalidomide under the original application from Devatis Inc., enabling market access for this established cancer the…
-
EMA approval · 2025-05-12EMA Authorised: Pomalidomide Zentiva (Pomalidomide) — Zentiva, k.s.
Pomalidomide Zentiva has been authorised for use in multiple myeloma by the EMA; it represents a generic version of pomalidomide.
-
FDA approval · 2025-03-26FDA Approved: PLERIXAFOR — Supplemental Application (Eugia US LLC)
FDA approved a supplemental application for a generic version of Plerixafor submitted by Eugia US LLC.
-
FDA approval · 2025-03-26FDA Approved: PLERIXAFOR — Supplemental Application (Novadoz Pharmaceuticals LLC)
The FDA approved a supplemental application for Plerixafor filed by Novadoz Pharmaceuticals LLC, related to changes to labeling and/or indic…
-
FDA approval · 2025-03-03FDA Approved: LENALIDOMIDE — Original Application (BIOCON PHARMA INC.,)
FDA approved Biocon Pharma Inc.'s lenalidomide as an original ANDA, enabling a generic version of the cancer drug. Indications include multi…
-
FDA approval · 2025-02-26FDA Approved: POMALIDOMIDE — Supplemental Application (Apotex Corp.)
The FDA approved a supplemental application from Apotex Corp. for pomalidomide, allowing the generic version of pomalidomide to be marketed …
-
EMA approval · 2025-02-13EMA Authorised: Bortezomib Fresenius Kabi (bortezomib) — Fresenius Kabi Deutschland GmbH
The European Medicines Agency authorised Bortezomib Fresenius Kabi for the treatment of multiple myeloma, with the active substance bortezom…
-
FDA approval · 2025-01-31FDA Approved: LENALIDOMIDE — Original Application (Amneal Pharmaceuticals NY LLC)
FDA approved Amneal Pharmaceuticals NY LLC's generic lenalidomide (LENALIDOMIDE) under an Original Application (ANDA 216213).
-
EMA approval · 2025-01-22EMA Authorised: Thalidomide BMS (previously Thalidomide Celgene) (thalidomide) — Bristol-Myers Squibb Pharma EEIG
The EMA authorised thalidomide (Bristol-Myers Squibb) for the treatment of multiple myeloma in the EU, with Bristol-Myers Squibb Pharma EEIG…
-
EMA approval · 2025-01-13EMA Authorised: Pepaxti (Melphalan flufenamide hydrochloride) — Oncopeptides AB (publ)
The European Medicines Agency authorised Pepaxti (melphalan flufenamide hydrochloride) for multiple myeloma, with Oncopeptides AB (publ) as …